A 90 day repeated oral toxicity study on plantamajoside concentrate from Plantago asiatica

Byung Gyu Park, Hyun Sun Lee, Sung Hoon Jung, Chung Oui Hong, Hye Jin Won, Ho Young Park, Yung Sun Ryu, Sung-Joon Lee, Kyoung Heon Kim, Kuen Woo Park, Kwang Won Lee

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Plantago asiatica is distributed widely in East Asia. Since ancient times it has been used as a diuretic to treat acute urinary infections, and as an antiinflammatory, antiasthmatic, antioxidant, antibacterial, antihyperlipidemic and antihepatitis drug. The major compound, plantamajoside from P. asiatica, which is used as a marker compound in chemotaxonomic studies, was reported to have antibacterial activity, inhibition activity against cAMP phosphodiesterase and 5-lipoxygenase and antioxidant activity. However, there are no reports on the safety of plantamajoside. This study assessed the toxic effects of plantamajoside concentrate (PC), the purity of which was above 80%, in rats following administration at dose levels of 0, 500, 1000 and 2000 mg/kg body weight/day for 13 weeks, as recommended by the OECD guidelines. The results showed that there were no differences in body weight, food intake, water consumption, relative organ weight or the hematological and serum biochemical values among the different dosage groups. No death or abnormal clinical signs were observed during the experimental period. Therefore, the results suggested that no observed adverse effect level (NOAEL) of the PC in rats after oral administration is considered to be greater than 2000 mg/kg in rats under the conditions employed in this study.

Original languageEnglish
Pages (from-to)1118-1123
Number of pages6
JournalPhytotherapy Research
Volume21
Issue number12
DOIs
Publication statusPublished - 2007 Dec 1

Fingerprint

Plantago
Toxicity
Rats
Antioxidants
Body Weight
Type 5 Cyclic Nucleotide Phosphodiesterases
Anti-Asthmatic Agents
Hypolipidemic Agents
No-Observed-Adverse-Effect Level
Arachidonate 5-Lipoxygenase
Far East
Organ Size
Poisons
Diuretics
Drinking
Oral Administration
Anti-Inflammatory Agents
Eating
Guidelines
Safety

Keywords

  • NOAEL
  • Phytochemicals
  • Plantaginaceae
  • Plantago asiatica
  • Plantamajoside
  • Toxicity

ASJC Scopus subject areas

  • Drug Discovery
  • Organic Chemistry
  • Pharmacology

Cite this

Park, B. G., Lee, H. S., Jung, S. H., Hong, C. O., Won, H. J., Park, H. Y., ... Lee, K. W. (2007). A 90 day repeated oral toxicity study on plantamajoside concentrate from Plantago asiatica. Phytotherapy Research, 21(12), 1118-1123. https://doi.org/10.1002/ptr.2217

A 90 day repeated oral toxicity study on plantamajoside concentrate from Plantago asiatica. / Park, Byung Gyu; Lee, Hyun Sun; Jung, Sung Hoon; Hong, Chung Oui; Won, Hye Jin; Park, Ho Young; Ryu, Yung Sun; Lee, Sung-Joon; Kim, Kyoung Heon; Park, Kuen Woo; Lee, Kwang Won.

In: Phytotherapy Research, Vol. 21, No. 12, 01.12.2007, p. 1118-1123.

Research output: Contribution to journalArticle

Park, BG, Lee, HS, Jung, SH, Hong, CO, Won, HJ, Park, HY, Ryu, YS, Lee, S-J, Kim, KH, Park, KW & Lee, KW 2007, 'A 90 day repeated oral toxicity study on plantamajoside concentrate from Plantago asiatica', Phytotherapy Research, vol. 21, no. 12, pp. 1118-1123. https://doi.org/10.1002/ptr.2217
Park, Byung Gyu ; Lee, Hyun Sun ; Jung, Sung Hoon ; Hong, Chung Oui ; Won, Hye Jin ; Park, Ho Young ; Ryu, Yung Sun ; Lee, Sung-Joon ; Kim, Kyoung Heon ; Park, Kuen Woo ; Lee, Kwang Won. / A 90 day repeated oral toxicity study on plantamajoside concentrate from Plantago asiatica. In: Phytotherapy Research. 2007 ; Vol. 21, No. 12. pp. 1118-1123.
@article{b97d05d910314689b69d3e15f377917e,
title = "A 90 day repeated oral toxicity study on plantamajoside concentrate from Plantago asiatica",
abstract = "Plantago asiatica is distributed widely in East Asia. Since ancient times it has been used as a diuretic to treat acute urinary infections, and as an antiinflammatory, antiasthmatic, antioxidant, antibacterial, antihyperlipidemic and antihepatitis drug. The major compound, plantamajoside from P. asiatica, which is used as a marker compound in chemotaxonomic studies, was reported to have antibacterial activity, inhibition activity against cAMP phosphodiesterase and 5-lipoxygenase and antioxidant activity. However, there are no reports on the safety of plantamajoside. This study assessed the toxic effects of plantamajoside concentrate (PC), the purity of which was above 80{\%}, in rats following administration at dose levels of 0, 500, 1000 and 2000 mg/kg body weight/day for 13 weeks, as recommended by the OECD guidelines. The results showed that there were no differences in body weight, food intake, water consumption, relative organ weight or the hematological and serum biochemical values among the different dosage groups. No death or abnormal clinical signs were observed during the experimental period. Therefore, the results suggested that no observed adverse effect level (NOAEL) of the PC in rats after oral administration is considered to be greater than 2000 mg/kg in rats under the conditions employed in this study.",
keywords = "NOAEL, Phytochemicals, Plantaginaceae, Plantago asiatica, Plantamajoside, Toxicity",
author = "Park, {Byung Gyu} and Lee, {Hyun Sun} and Jung, {Sung Hoon} and Hong, {Chung Oui} and Won, {Hye Jin} and Park, {Ho Young} and Ryu, {Yung Sun} and Sung-Joon Lee and Kim, {Kyoung Heon} and Park, {Kuen Woo} and Lee, {Kwang Won}",
year = "2007",
month = "12",
day = "1",
doi = "10.1002/ptr.2217",
language = "English",
volume = "21",
pages = "1118--1123",
journal = "Phytotherapy Research",
issn = "0951-418X",
publisher = "John Wiley and Sons Ltd",
number = "12",

}

TY - JOUR

T1 - A 90 day repeated oral toxicity study on plantamajoside concentrate from Plantago asiatica

AU - Park, Byung Gyu

AU - Lee, Hyun Sun

AU - Jung, Sung Hoon

AU - Hong, Chung Oui

AU - Won, Hye Jin

AU - Park, Ho Young

AU - Ryu, Yung Sun

AU - Lee, Sung-Joon

AU - Kim, Kyoung Heon

AU - Park, Kuen Woo

AU - Lee, Kwang Won

PY - 2007/12/1

Y1 - 2007/12/1

N2 - Plantago asiatica is distributed widely in East Asia. Since ancient times it has been used as a diuretic to treat acute urinary infections, and as an antiinflammatory, antiasthmatic, antioxidant, antibacterial, antihyperlipidemic and antihepatitis drug. The major compound, plantamajoside from P. asiatica, which is used as a marker compound in chemotaxonomic studies, was reported to have antibacterial activity, inhibition activity against cAMP phosphodiesterase and 5-lipoxygenase and antioxidant activity. However, there are no reports on the safety of plantamajoside. This study assessed the toxic effects of plantamajoside concentrate (PC), the purity of which was above 80%, in rats following administration at dose levels of 0, 500, 1000 and 2000 mg/kg body weight/day for 13 weeks, as recommended by the OECD guidelines. The results showed that there were no differences in body weight, food intake, water consumption, relative organ weight or the hematological and serum biochemical values among the different dosage groups. No death or abnormal clinical signs were observed during the experimental period. Therefore, the results suggested that no observed adverse effect level (NOAEL) of the PC in rats after oral administration is considered to be greater than 2000 mg/kg in rats under the conditions employed in this study.

AB - Plantago asiatica is distributed widely in East Asia. Since ancient times it has been used as a diuretic to treat acute urinary infections, and as an antiinflammatory, antiasthmatic, antioxidant, antibacterial, antihyperlipidemic and antihepatitis drug. The major compound, plantamajoside from P. asiatica, which is used as a marker compound in chemotaxonomic studies, was reported to have antibacterial activity, inhibition activity against cAMP phosphodiesterase and 5-lipoxygenase and antioxidant activity. However, there are no reports on the safety of plantamajoside. This study assessed the toxic effects of plantamajoside concentrate (PC), the purity of which was above 80%, in rats following administration at dose levels of 0, 500, 1000 and 2000 mg/kg body weight/day for 13 weeks, as recommended by the OECD guidelines. The results showed that there were no differences in body weight, food intake, water consumption, relative organ weight or the hematological and serum biochemical values among the different dosage groups. No death or abnormal clinical signs were observed during the experimental period. Therefore, the results suggested that no observed adverse effect level (NOAEL) of the PC in rats after oral administration is considered to be greater than 2000 mg/kg in rats under the conditions employed in this study.

KW - NOAEL

KW - Phytochemicals

KW - Plantaginaceae

KW - Plantago asiatica

KW - Plantamajoside

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=37849009344&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37849009344&partnerID=8YFLogxK

U2 - 10.1002/ptr.2217

DO - 10.1002/ptr.2217

M3 - Article

C2 - 17622978

AN - SCOPUS:37849009344

VL - 21

SP - 1118

EP - 1123

JO - Phytotherapy Research

JF - Phytotherapy Research

SN - 0951-418X

IS - 12

ER -